Guardant Health has entered a strategic partnership with Flatiron Health to build a proprietary, cloud-based information platform integrating liquid biopsy based genomic testing with clinical treatment and outcomes data for the treatment of cancer.
Combining advanced clinical insights from the Flatiron Health OncologyCloud platform with genomic data from Guardant Health's Guardant360 liquid biopsy platform, it will support the accelerated development of targeted therapies for cancer.
Flatiron Health co-founder Nat Turner said: "Integrating clinical and genomic information has the potential to dramatically improve cancer treatment and advance therapy development.
"Flatiron Health and Guardant Health's collective technology, oncology know-how and genomic expertise will deliver an advanced, cloud-based platform to enhance patient care."
The new platform is expected to allow life science companies to uncover new molecular targets, expand clinical indications, reduce the time to recruit and select patients for trials, and also longitudinally follow patients and their progress over time.
Guardant Health co-founder Helmy Eltoukhy said: "Today, oncologists and patients are demanding new therapies matched to their underlying tumour genomics to improve cancer treatment.
"Guardant360 removes the tissue barrier to accessing this genomic information in real-time.
"When combined with Flatiron Health's clinical data, this will significantly accelerate timelines for drug development, enabling many new treatment options for millions of cancer patients."
Both companies will jointly work to develop products that integrate anonymous clinical treatment and outcomes data with genomic data for patients who have undergone testing with the Guardant360 platform.
The Health Insurance Portability and Accountability Act compliant information platform is scheduled to be made available to life science companies during the first half of 2016.